Automatic Determination of Anti-Coagulation Status with NDF-RT

Total Page:16

File Type:pdf, Size:1020Kb

Automatic Determination of Anti-Coagulation Status with NDF-RT Proceedings of the 13th ISMB'2010 SIG meeting "Bio-ontologies" 2010:140-143. Automatic determination of anticoagulation status with NDF-RT Olivier Bodenreider*1, Fleur Mougin2 and Anita Burgun3 1 National Library of Medicine, Bethesda, Maryland, USA 2 LESIM, INSERM U897, ISPED, University Victor Segalen Bordeaux 2, France 3 INSERM U936, EA3888, School of Medicine, University of Rennes 1, IFR 140, France ABSTRACT tients at home, as it requires parenteral administration Objectives: To determine the anti-coagulation status of pa- (intravenous or subcutaneous route). tients, based on the list of medications they have been pre- From the perspective of clinical pharmacology, clopido- scribed, using the publicly available resource NDF-RT (Na- grel and warfarin are active moieties, while platelet aggre- tional Drug File Reference Terminology). Methods: We ex- gation inhibitors and anticoagulants are pharmacologic plored the legacy VA classes and we refined the definition of classes. Classes are typically established in reference to external pharmacologic classes (EXT) in NDF-RT in order to some of the properties of the active moiety, with respect to enable inferences by a description logic classifier. Results: chemistry, physiology, metabolism and therapeutic intent Of the 9 patients with a positive anticoagulation status, the (Carter, et al., 2006). For example, the classes platelet ag- VA class approach identified only 6, while the EXT approach gregation inhibitors and anticoagulants refer to the physi- identified 8. Conclusions: This preliminary experiment illu- ologic effect of drugs decreasing platelet aggregation and strates the benefits of using a refined definition of external coagulation, respectively. In contrast, the class cardiac gly- pharmacologic classes in NDF-RT. Further investigation is coside refers to the chemical structure of drugs such as di- needed. Supplementary figure: Representation of the drug goxin, while the class antianginal refers to the therapeutic clopidogrel in NDF-RT, available at: properties of some drugs on angina pectoris. Some classes http://mor.nlm.nih.gov/pubs/supp/2010-bioonto-ob/index.html. are also defined in reference to several properties, e.g., ni- trate vasodilator, referring to both the chemical structure of 1 INTRODUCTION nitrates and their relaxing action on the musculature of Patients suffering from heart failure are increasingly treated blood vessels (physiologic effect). with implantable cardioverter defibrillators (ICD) and bene- The main objective of this study is to determine the anti- fit from home monitoring. In this context of telecardiology, coagulation status of patients from the AKENATON ICDs send remote alerts about arrhythmic episodes to phy- project, based on the list of medications they have been pre- sicians, who have to determine their emergency level. The scribed. A secondary objective is to evaluate the extent to objective of the French AKENATON project is to integrate which the publicly available resource NDF-RT (National the data transmitted by the ICDs with their clinical context, Drug File Reference Terminology) provides appropriate in order to improve alert management (AKENATON, 2010; classes and drug-class membership relations to support such Burgun, et al., 2010). For example, in case of atrial fibrilla- a use case. tion, the thromboembolic risk depends on the medications taken by the patient. The formation of a clot in the heart is a 2 BACKGROUND complex process that involves platelets and multiple sub- The National Drug File Reference Terminology (NDF-RT) stances called clotting factors. is a resource developed by the Department of Veterans Af- Medications that prevent blood clots from occurring in- fairs (VA) Veterans Health Administration, as an extension clude platelet aggregation inhibitors and anticoagulants of the VA National Drug File (Lincoln, et al., 2004). Like (Weimar, et al., 2009). Platelet aggregation inhibitors, such other modern biomedical terminologies, NDF-RT was de- as clopidogrel, work by decreasing the ability of platelets to veloped using description logics and is available in several aggregate. Aspirin also makes platelets less likely to form formats, including XML and OWL. The version used in this blood clots. Oral anticoagulants, such as warfarin, decrease study is the latest OWL version available, dated September the body’s ability to form blood clots by blocking the for- 1, 2009, downloaded from the NCI website1. This version mation of vitamin K-dependent clotting factors. Another covers 1751 active moieties (level = ingredient) and 4695 anticoagulant, heparin, is less likely to be prescribed to pa- clinical drugs (level = VA product). Two independent kinds of drug classes are represented in NDF-RT: legacy VA * To whom correspondence should be addressed. 1 ftp://ftp1.nci.nih.gov/pub/cacore/EVS/NDF-RT/ 1 O. Bodenreider et al. classes and “external pharmacologic classes” defined in cardioverter defibrillators. The list of medications for each reference to some of the properties of the active moiety. patient was extracted manually from the text of the records, Legacy VA classes are simply listed as parents of clinical yielding a total of 46 medications (3.6 per patient on aver- drugs (“VA Products”). For example, the drug CLOPIDO- age). Medication names were mapped manually to generic GREL BISULFATE 75MG TAB is a subclass of PLATELET ingredient names. This step was necessary, because of loca- AGGREGATION INHIBITORS. There are 485 such VA lized brand names (e.g., Lasilix in France vs. Lasix in the classes, organized in a shallow hierarchy. The set of VA U.S. for furosemide). A total of 23 unique ingredient names classes forms a classification system, i.e., accommodates were identified. Ingredients were mapped to NDF-RT iden- virtually any drug through residual classes (e.g., BLOOD tifiers automatically through the RxNav API (Peters and PRODUCTS, OTHER). In most cases, a clinical drug is as- Bodenreider, 2008). In four cases, no NDF-RT correspon- sociated with one and only one class. No relations are stated dence was found for the ingredient. In 3 of these cases, the between these classes and drug properties. corresponding ingredient was simply discarded, as it was External pharmacologic classes are defined in reference not central to our investigation (betahistine, an antivertigo to the properties of active moieties. A given class can reflect drug; trimetazidine, an anti-anginal agent; and zopiclone, a one property (e.g., Platelet Aggregation Inhibitor2, in refer- hypnotic agent). The remaining ingredient with no mapping ence to the physiologic effect Decreased Platelet Aggrega- to NDF-RT was the anticoagulant fluindione – prescribed in tion) or multiple properties (e.g., Antiarrhythmic, in refer- Europe, but not in the U.S. – to which we substituted a simi- ence to the therapeutic intent – both preventative and cura- lar drug, anisindione. Finally, in one case, the medication tive – expressed as may_prevent Arrhythmia and may_treat was expressed not as a clinical drug, but directly as a class Arrhythmia). There are 408 such external pharmacologic (Vitamin K Antagonist). classes, with no hierarchical organization. Although active 3.2 Establishing relations between ingredients moieties are also described in terms of similar properties (e.g., CLOPIDOGREL, in reference to the physiologic effect and external pharmacologic classes Decreased Platelet Aggregation), no relations are found Unlike for legacy VA classes, no relations are present in the between active moieties (ingredients) and external pharma- OWL version of NDF-RT between drugs and external cologic classes. Moreover, from the perspective of descrip- pharmacologic classes. Moreover, because the external tion logics (DL), because all concepts in NDF-RT are primi- pharmacologic classes are all primitive concepts, no such tive concepts (i.e., no necessary and sufficient conditions are relations can be inferred by a DL classifier. In order to sup- provided for external pharmacologic classes), no inferred port such inference, we modified the OWL version of NDF- relations can be computed automatically by a DL classifier RT in the following ways. between active moieties and external pharmacologic classes. Step 1. We transformed the primitive concepts for exter- In practice, CLOPIDOGREL and Platelet Aggregation Inhi- nal pharmacologic classes into defined classes by specifying bitor are not related – directly or through inference – in the a set of necessary and sufficient conditions for the class current OWL version of NDF-RT. (adding an owl:equivalentClass (≡) axiom). The re- Several groups have investigated various aspects of NDF- strictions based on has_TC are specific to external pharma- RT, including coverage (Brown, et al., 2004), representation cologic classes (providing links to high-level therapeutic of specific drug properties (Rosenbloom, et al., 2003), and class concepts) and not used in the ingredients. For this rea- fitness for purpose in applications, such as linkage to indica- son, they were left out of the necessary and sufficient condi- tions (Burton, et al., 2008) and detection of drug intolerance tions. (Schadow, 2009). Our present investigation of NDF-RT is Step 2. Because the therapeutic intent properties also performed in the context of an application. The specific may_treat and may_prevent are not always used consistently contribution of our study is to leverage (and improve) the in the ingredients compared to the external pharmacologic description logic
Recommended publications
  • This Table Summarizes Changes to the HF Qxq As of 10/11/2019 Question
    Updated HFS Instructions (QxQs) This table summarizes changes to the HF QxQ as of 10/11/2019 Question in HF QxQ Description of Changes in HF QXQ General Instructions, pg. 3 Clarification added to rules for history Q29.d.10., pg. 40 Clarification made on how to record pulmonary hypertention Q29.d.14., pg. 41 Clarification made on how to record diastolic dysfunction Q42., pg. 42 Clarification made on how to record troponin I Section VII: Medication, pg. 54 Clarificaiton made on how to record medications Appendix A, pg. 61 Updated list of medications Edoxaban (ACOAG, Generic) Lixiana (ACOAG, Trade) Prexxartan (ARB, Trade) INSTRUCTIONS FOR COMPLETING HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM HFS Version C, 10/1/2015 HFA Version D, 10/1/2015 HF QxQ, 10/11/2019 Table of Contents Page General Instructions……………………………………………………………….. 2 Specific Items………………………………………………………………………. 3 Section l: Screening for Decompensation………………………………….. 5 Section ll: History of Heart Failure…………………………………………... 10 Section lll: Medical History ………………………………………………….. 13 Section lV: Physical Exam - Vital Signs…………………………………….. 24 Section V: Physical Exam - Findings……………………………………….. 26 Section Vl: Diagnostic Tests…………………………………………………. 31 Section Vll: Biochemical Analyses………………………………………….. 48 Section Vlll: Interventions…………………………………………………….. 51 Section lX: Medications………………………………………………………. 54 Section X: Complications Following Events………………………………… 59 Section Xl: Administrative……………………………………………………. 60 Appendix A: ARIC Heart Failure/Cardiac Drugs: ………………………………. 61 Alphabetical Sort Appendix B: Potential Scenarios of the Onset of Heart………………………. 73 Failure Event or Decompensation HF QxQ 10/11/2019 Page 1 of 73 General Instructions The HFAA form was initially used for all discharges selected for HF surveillance. It was replaced by the HFAB and HFSA forms and then updated June 2012 with HFAC and HFSB.
    [Show full text]
  • MIRADON FPO Brand of Anisindione Tablets
    R 1 2 3 4 5 3 4 F-16099775 1898 ® MIRADON FPO brand of anisindione Tablets DESCRIPTION MIRADON Tablets contain a syn- thetic anticoagulant, anisindione, an indanedione derivative. Each tablet contains 50 mg anisin- dione. They also contain: corn starch, FD&C Red No. 3, gelatin, lactose, and hydrogenated cotton- seed oil. ACTIONS Like phenindione, to which it is re- lated chemically, anisindione exercises its thera- peutic action by reducing the prothrombin activity of the blood. INDICATIONS Anisindione is indicated for the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrilla- tion with embolization, the prophylaxis and treat- ment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion. CONTRAINDICATIONS All contraindications to oral anticoagulant therapy are relative rather than absolute. Contraindications should be evaluated for each patient, giving consideration to the need for and the benefits to be achieved by anticoagu- lant therapy, the potential dangers of hemor- rhage, the expected duration of therapy, and the quality of patient monitoring and compliance. Hemorrhagic Tendencies or Blood Dyscrasias: In general, oral anticoagulants are contraindi- cated in patients who are bleeding or who have hemorrhagic blood dyscrasias or hemorrhagic tendencies (eg, hemophilia, polycythemia vera, purpura, leukemia) or a history of bleeding dia- thesis. They are contraindicated in patients with recent cerebral hemorrhage, active ulceration of the gastrointestinal tract, including ulcerative colitis, or open ulcerative, traumatic, or surgical wounds. Oral anticoagulants may be contraindi- cated in patients with recent or contemplated brain, eye, or spinal cord surgery or prostatec- tomy, and in those undergoing regional or lumbar block anesthesia or continuous tube drainage of the small intestine.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
    US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII.
    [Show full text]
  • Some Aspects of the Pharmacology of Oral Anticoagulants
    Some aspects of the pharmacology of oral anticoagulants The pharmacology of oral anticoagulants ls discussed with particular rejerence to data of value in the management of therapy. The importance of individual variability in response and drug interaction is stressed. Other effects of these agents which may have clinical utility are noted. William W. Coon, M.D., and Park W. Willis 111, M.D., Ann Arbor, Mich. The Departments of Surgery (Section of General Surgery) and Medicine, University of Michigan Medical School In the twenty-five years sinee the isola­ dividual struetural features but by a com­ tion of the hemorrhagie faetor in spoiled bination of several: molecular shape, in­ sweet clever," the gradually inereasing creased aetivity with 6 membered hetero­ utilization of oral antieoagulants for the eyclic rings with a substituent in position prevention and therapy of thromboembolie 8 and with a methoxyl rather than a free disease has made them one of the most hydroxl group. Also important is the dernon­ widely used groups of pharmacologic stration that levorotatory warfarin is seven agents. This review is restrieted to as­ times more aetive than its enantiomer.F" peets of the pharmaeology of these agents As Hunter and Shepherd'" have pointed whieh may be important to their proper out, the failure to obtain a precise cor­ clinieal utilization. relation between strueture and antieoagu­ lant aetivity is "not surprising in view of Relation of structure to function the influence of small struetural changes The oral antieoagulants have been di­ on sueh variables as solubility, rate of ab­ vided into four main groups on the basis sorption, ease of distribution, degree of of ehemieal strueture (Fig.
    [Show full text]
  • Home Medication Form
    DIVISION OF EDUCATION • SURGICAL PATIENT EDUCATION Medication and Surgery Inspiring Quality: BEFORE YOUR OPERATION Highest Standards, Better Outcomes Your medications may have to be adjusted before your operation. Some medication can affect your recovery and response to anesthesia. Write down all of the mediations you are taking. A blank medication list is provided if you need it. Make a list. Your list should include: ● Any prescription medications ● Over-the-counter (OTC) medications (such as aspirin or Tylenol) ● Herbs, vitamins, and supplements ● Tell your doctor if you smoke and how often you drink alcohol or use other recreational drugs. Check with your List of medications that affect blood clotting:* doctor about: ● Antiplatelet Medication: Anagrelide (Agrylin®), aspirin (any brand, all doses), cilostazol (Pletal®), clopidogrel (Plavix®), ● When to stop taking all vitamins, dipyradamole (Persantine®), dipyridamole/aspirin (Aggrenox®), herbs, and diet supplements. enteric-coated aspirin (Ecotrin®), ticlopidine (Ticlid®) This could be 10 to 14 days ● ® before and up to 7 days after Anticoagulant Medication: Anisindione (Miradon ), Arixtra, ® your test or operation. enoxaparin (Lovenox ) injection, Fragmin, heparin injection, Pradaxa, pentosan polysulfate (Elmiron®), warfarin (Coumadin®), Xerelto ● How to take your medication on ● the morning of your operation. You Nonsteroidal Anti-Inflammatory Drugs: Celebrex, diclofenac ® ® ® ® may be instructed to take some (Voltaren , Cataflam ), diflunisal (Dolobid ), etodolac (Lodine ), fenoprofen
    [Show full text]
  • Appendix C Medication Tables
    Appendix C Medication Tables Note: The medication tables are not meant to be inclusive lists of all available therapeutic agents. Approved medication tables will be updated regularly. Discrepancies must be reported. See Resource Section of this manual for additional contact information. Release Notes: Aspirin Table Version 1.0 Table 1.1 Aspirin and Aspirin-Containing Medications Acetylsalicylic Acid Acuprin 81 Alka-Seltzer Alka-Seltzer Morning Relief Anacin Arthritis Foundation Aspirin Arthritis Pain Ascriptin Arthritis Pain Formula ASA ASA Baby ASA Baby Chewable ASA Baby Coated ASA Bayer ASA Bayer Children's ASA Buffered ASA Children's ASA EC ASA Enteric Coated ASA/Maalox Ascriptin Aspergum Aspir-10 Aspir-Low Aspir-Lox Aspir-Mox Aspir-Trin Aspirbuf Aspircaf Aspirin Aspirin Baby Aspirin Bayer Aspirin Bayer Children's Aspirin Buffered Aspirin Child Aspirin Child Chewable Aspirin Children's Aspirin EC Aspirin Enteric Coated Specifications Manual for National Appendix C-1 Hospital Quality Measures Table 1.1 Aspirin and Aspirin-Containing Medications (continued) Aspirin Litecoat Aspirin Lo-Dose Aspirin Low Strength Aspirin Tri-Buffered Aspirin, Extended Release Aspirin/butalbital/caffeine Aspirin/caffeine Aspirin/pravachol Aspirin/pravastatin Aspirtab Bayer Aspirin Bayer Aspirin PM Extra Strength Bayer Children’s Bayer EC Bayer Enteric Coated Bayer Low Strength Bayer Plus Buffered ASA Buffered Aspirin Buffered Baby ASA Bufferin Bufferin Arthritis Strength Bufferin Extra Strength Buffex Cama Arthritis Reliever Child’s Aspirin Coated Aspirin
    [Show full text]
  • I ©Copyright 2012 Clara K. Hsia
    ©Copyright 2012 Clara K. Hsia i Biochemical and Mechanistic Studies of the Interactions Between Vitamin K Antagonists and Vitamin K Epoxide Reductase Clara K. Hsia A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2012 Reading Committee: Allan E. Rettie, Chair Kent L. Kunze William M. Atkins Program Authorized to Offer Degree: Medicinal Chemistry University of Washington Abstract Biochemical and Mechanistic Studies of the Interactions Between Vitamin K Antagonists and Vitamin K Epoxide Reductase Clara K. Hsia Chair of the Supervisory Committee: Professor Allan E. Rettie Department of Medicinal Chemistry The studies that are presented in this dissertation have; (i) established a mechanism by which warfarin dose response is modulated by VKORC1 genotype under optimized conditions for kinetic analysis of human vitamin K epoxide reductase (VKOR) catalytic activity, (ii) evaluated previously suggested irreversible and reversible mechanisms of VKOR inhibition by vitamin K antagonists (VKAs), and (iii) elucidated the role of tyrosine 139 in the catalytic center and inhibitor binding site of VKOR. Firstly, observation of VKOR activity in human liver microsomes (HLMs) under varied experimental conditions demonstrated that human VKOR is a highly labile enzyme. Under optimal conditions, evaluation of genotyped HLMs for downstream effects of altered VKORC1 mRNA expression revealed a relationship between the VKORC1 B haplotype and increased the catalytic activity and protein expression of VKOR. This demonstrates that warfarin dose is regulated through a transcriptional mechanism wherein higher levels of VKORC1 mRNA translate to increased protein expression and associated enzymatic activity of VKOR, thus requiring a higher dose of warfarin to maintain the same target level of anticoagulation.
    [Show full text]
  • Utah Medicaid Pharmacy and Therapeutics Committee Drug
    Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review Non-Selective Oral Nonsteroidal Anti-Inflammatory Drugs AHFS Classification: 28:08.04.92 Other Nonsteroidal Anti-inflammatory Agents Diclofenac Etodolac Fenoprofen Flurbiprofen Ibuprofen Indomethacin Ketoprofen Ketorolac Mefenamic Acid Meloxicam Nabumetone Naproxen Oxaprozin Piroxicam Sulindac Tolmetin Final Report April 2018 Review prepared by: Elena Martinez Alonso, B.Pharm., Medical Writer Vicki Frydrych, B.Pharm., Pharm.D., Clinical Pharmacist Valerie Gonzales, Pharm.D., Clinical Pharmacist Joanita Lake, B.Pharm., MSc EBHC (Oxon), Research Assistant Professor, Clinical Pharmacist Michelle Fiander, MA, MLIS, Research Assistant Professor, Evidence Synthesis Librarian Joanne LaFleur, PharmD, MSPH, Associate Professor University of Utah College of Pharmacy University of Utah College of Pharmacy, Drug Regimen Review Center Copyright © 2018 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved 1 Contents Executive Summary ...................................................................................................................................... 3 Introduction ................................................................................................................................................... 6 Table 1. FDA-Approved Oral Non-selective NSAIDs......................................................................... 7 Table 2. FDA-Approved Indication for Oral Non-selective NSAIDs ...............................................
    [Show full text]
  • Effectiveness and Safety of Non-Vitamin K Antagonist Oral
    Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Compared to Vitamin K Antagonists for the Treatment of Ventricular Thrombus: A Systematic Review and Meta-analysis of Observational Studies Qing Yang Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital Liyun He PUMCH: Peking Union Medical College Hospital Yan Liang ( [email protected] ) Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital https://orcid.org/0000-0002-9053-9389 Research Keywords: ventricular thrombus, non-vitamin K antagonists, oral anticoagulants, warfarin Posted Date: December 1st, 2020 DOI: https://doi.org/10.21203/rs.3.rs-115338/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/21 Abstract Background To compare the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) on the rate of thrombus resolution and clinical outcomes. Method MEDLINE, PUBMED, EMBASE, Cochrane Library, Web of Science, China National Knowledge Infrastructure Database and Wanfang Database, were searched up to August 16, 2020. Observational studies of patients with ventricular thrombus which compared the effect of two agents on the primary outcome were included. The primary outcome was rate of thrombus resolution, and the secondary outcomes were systemic embolism, bleeding and all-cause death. Odds ratio (OR) and 95% condential intervals (CI) were utilized for the pooled results. Result Eight studies with 905 participants were nally included. Among these cases, 66.6% of patients received VKAs and 33.4% of patients received NOACs. Rivaroxaban (71.9%) was the most commonly used NOACs.
    [Show full text]
  • Warfarin-Induced Leukocytoclastic Vasculitis
    CONTINUING MEDICAL EDUCATION Warfarin-Induced Leukocytoclastic Vasculitis Bahareh Yaghoubian, PharmD; Binh Ngo, MD; May Mak, PharmD; Enrique Ostrzega, MD; Jane Tesoro, PharmD; Gladys H. Moriguchi Mitani, PharmD GOAL To understand leukocytoclastic vasculitis (LV) to better manage patients with the condition OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Recognize the presentation of LV. 2. Explain the factors contributing to drug-induced LV. 3. Discuss treatments and preventive strategies for LV. CME Test on page 348. This article has been peer reviewed and is accredited by the ACCME to provide continuing approved by Michael Fisher, MD, Professor of medical education for physicians. Medicine, Albert Einstein College of Medicine. Albert Einstein College of Medicine designates Review date: May 2005. this educational activity for a maximum of 1 This activity has been planned and implemented category 1 credit toward the AMA Physician’s in accordance with the Essential Areas and Policies Recognition Award. Each physician should of the Accreditation Council for Continuing Medical claim only that credit that he/she actually spent Education through the joint sponsorship of Albert in the activity. Einstein College of Medicine and Quadrant This activity has been planned and produced in HealthCom, Inc. Albert Einstein College of Medicine accordance with ACCME Essentials. Drs. Yaghoubian, Ngo, Mak, Ostrzega, and Tesoro report no conflict of interest. Dr. Mitani is in the speakers program for Aventis Pharmaceuticals Inc and GlaxoSmithKline. The authors discuss off-label use for enoxaparin. Dr. Fisher reports no conflict of interest. Skin reactions associated with oral coumarin- Accepted for publication February 25, 2005.
    [Show full text]
  • Medications & Supplements to Stop Before Surgery & Injections
    Medications & Supplements to Stop Before Surgery & Injections Some medications and dietary supplements can contribute to bruising, bleeding or other problems if taken before injections (Botox, Fillers) or surgery. These must be stopped 2 weeks before! Most of the supplements and drugs below can contribute to coagulation problems (Blood Thinners) and should be stopped 2 weeks before injections or surgery. The asterisk (*) identifies those that could affect anesthesia and healing and relate mostly to surgery. If a medication on the list has been prescribed by your doctor for medical reasons (Plavix, Coumadin, Aspirin for a stent, Prednisone, etc.), DO NOT STOP the medication without first discussing it with your physician. Please let us know if you have been prescribed any of these medications so we can help you formulate a safe plan. The list below is ever changing with new medications and more information on old ones. Therefore, it should not be considered complete. If you are not sure about a product, ask us and we will research it. If you were prescribed Vitamedica Vitamins before surgery, these are safe to use and are designed for the peri- operative period. The doctors will advise you when you can resume supplements and medications after surgery (usually 7 days). ASPIRIN & RELATED Acetyl Salicylic Acid Mesalamine (Asacol, Apriso, Lialda, Pentasa, Canasa) (Anacin, Alka Seltzer, Ascriptin, Bufferin, Bayer, Excedrin, etc) Olsalazine (Dipentum) Aminosalicylic Acid Sodium Salicylate Bismuth Subsalicylate (Pepto Bismol) Sulfasalazine (Azulfidine)
    [Show full text]
  • Medications to Avoid
    1 Patient Name:___________________ Medications to Avoid If you are taking any medications on this list, they should be discontinued 2 weeks prior to surgery and only acetaminophen products, such as Tylenol, should be taken for pain. All other medications – prescriptions, over- the-counter and herbal – that you are currently taking must be specifically cleared by Dr. Alexander or the Anesthesiologist prior to surgery. It is absolutely necessary that all of your current medications be specifically cleared by Dr. Alexander, the Anesthesiologist or the nursing staff. Aspirin Medications to Avoid Affect blood clotting: 4-Way Cold Tabs 5- Cama Arthritis Pain Isollyl Improved Percodan products Aminosalicylic Acid Reliever Kaodene Phenaphen/Codeine #3 Acetilsalicylic Acid Carisoprodol Compound Lanorinal Pink Bismuth Actron Cataflam lbuprohm Piroxicam Adprin-B products Cheracol Lodine Propoxyphene Compound Aleve Choline Magnesium Lortab ASA products Alka-Seltzer products Trisalicylate Magan Robaxisal Amigesic Argesic-SA Choline Salicylate Magnaprin products Rowasa Anacin products Cope Magnesium Salicylate Roxeprin Anexsia w/Codeine Coricidin Magsal Saleto products Arthra-G Cortisone Medications Marnal Salflex Arthriten products Damason-P Marthritic Salicylate products Arthritis Foundation Darvon Compound-65 Mefenamic Acid Salsalate products Darvon/ASA Meprobamate Salsitab Arthritis Pain Formula Diclofenac Mesalamine Scot-Tussin Original 5- Arthritis Strength BC Dipenturn Methocarbarnol Action Powder Disalcid Micrainin Sine-off Arthropan Doan's
    [Show full text]